<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00921791</url>
  </required_header>
  <id_info>
    <org_study_id>GPPG 04465</org_study_id>
    <nct_id>NCT00921791</nct_id>
  </id_info>
  <brief_title>Efficacy of Home Blood Pressure Monitoring (MONITOR Study)</brief_title>
  <acronym>MONITOR</acronym>
  <official_title>Efficacy of Home Blood Pressure Monitoring to Improve Blood Pressure Control: a Randomized Controlled Trial With Ambulatory Blood Pressure Measurement</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hospital de Clinicas de Porto Alegre</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Conselho Nacional de Desenvolvimento Científico e Tecnológico</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Fundação de Amparo à Pesquisa do Estado do Rio Grande do Sul, Brazil</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Federal University of Health Science of Porto Alegre</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Hospital de Clinicas de Porto Alegre</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      High blood pressure is the main risk factor for cardiovascular disease worldwide,but its
      control rate is unsatisfactory. Home Blood Pressure Monitoring (HBPM) with automatic
      oscillometric devices and pharmaceutical care have been proposed as interventions to increase
      therapeutic compliance and to guide treatment decisions.

      The purpose of this study is to evaluate the effect of HBPM and of pharmaceutical care in
      blood pressure control measured through 24h ambulatory blood pressure monitoring (ABPM).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Home Blood Pressure Monitoring (HBPM) and Pharmaceutical care have been proposed to improve
      therapeutic compliance and to guide treatment decisions, but their effects on BP control are
      still under debate.

      This is a factorial randomized controlled trial including adult hypertensive patients under
      drug treatment but with office BP and 24h ABPM uncontrolled. Participants will be allocated
      to one of four groups: HBPM; HBPM and Pharmaceutical care; Pharmaceutical care; or control.
      All participants will receive usual care for high blood pressure. Participants will be
      followed for 60 days.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>April 2006</start_date>
  <completion_date type="Actual">June 2009</completion_date>
  <primary_completion_date type="Actual">January 2009</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Factorial Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Delta values for 24h ABPM between baseline and final ABPM measurements</measure>
    <time_frame>60 days</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Hypertension control</measure>
    <time_frame>60 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Average of systolic and diastolic blood pressure at the end of the study.</measure>
    <time_frame>60 days</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">136</enrollment>
  <condition>Hypertension</condition>
  <arm_group>
    <arm_group_label>Home Blood Pressure Monitoring</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Automatic oscillometric device for blood pressure measurement at home plus usual care.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>HBPM and Pharmaceutical care</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Automatic oscillometric device for blood pressure measurement at home and consultations with the pharmacists plus usual care.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Pharmaceutical care</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Consultations with the pharmacists plus usual care.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Usual care: participants are instructed to keep on their current antihypertensive medication and receive non-pharmacological recommendations for hypertension treatment.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>HBPM</intervention_name>
    <description>Automatic oscillometric device for home blood pressure measurement and usual care.</description>
    <arm_group_label>Home Blood Pressure Monitoring</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>HBPM and Pharmaceutical care</intervention_name>
    <description>Automatic oscillometric device for blood pressure measurement at home and consultations with the pharmacists</description>
    <arm_group_label>HBPM and Pharmaceutical care</arm_group_label>
    <other_name>HBPM</other_name>
  </intervention>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Pharmaceutical care</intervention_name>
    <description>consultations with the pharmacists</description>
    <arm_group_label>Pharmaceutical care</arm_group_label>
    <other_name>DADER method</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Usual care</intervention_name>
    <description>Consultation with the physician.</description>
    <arm_group_label>Control</arm_group_label>
    <other_name>Usual clinical practice.</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Office BP ≥140/90 mm Hg

          -  24h ABPM hypertension BP ≥130/80 mm Hg

          -  using at least one antihypertensive drug

        Exclusion Criteria:

          -  BP ≥ 180 / 110 mmHg)

          -  major cardiovascular events in the last six months

          -  acute or chronic diseases limiting the capacity to understand and to participate in
             the trial

          -  masked hypertension

          -  white-coat hypertension

          -  secondary hypertension

          -  pregnancy

          -  breastfeeding

          -  concurrent participation in another trial
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Sandra C. Fuchs, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Federal University of Rio Grande do Sul</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Hospital de Clínicas de Porto Alegre</name>
      <address>
        <city>Porto Alegre</city>
        <state>RS</state>
        <zip>90035-903</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Brazil</country>
  </location_countries>
  <verification_date>June 2009</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 15, 2009</study_first_submitted>
  <study_first_submitted_qc>June 15, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 16, 2009</study_first_posted>
  <last_update_submitted>June 15, 2009</last_update_submitted>
  <last_update_submitted_qc>June 15, 2009</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 16, 2009</last_update_posted>
  <responsible_party>
    <name_title>Sandra Costa Fuchs, MD, PhD</name_title>
    <organization>Hospital de Clínicas de Porto Alegre</organization>
  </responsible_party>
  <keyword>Hypertension</keyword>
  <keyword>Blood pressure</keyword>
  <keyword>Home Blood Pressure Monitoring</keyword>
  <keyword>Ambulatory Blood Pressure Monitoring</keyword>
  <keyword>Pharmaceutical care</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypertension</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

